ArticleJournal of inflammation research2024
The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score Predicts the Prognosis of Adults with Status Epilepticus: A Retrospective Study.
Article in Journal of inflammation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Comparative Analysis of Neutrophil-to-Lymphocyte Ratio, Systemic Immune-Inflammation Index, and Hemoglobin-Albumin-Lymphocyte-Platelet Score in Migraine.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been indicated to be a novel indicator that reflects systemic inflammation and is associated with the functional outcome in various neurological diseases. Since inflammation is closely involved in the pathogenesis of status epilepticus (SE), this study aimed to explore the predictive value of HALP for the prognosis of SE patients. Methods: In the retrospective study, we investigated and validated the predictive value of HALP for the prognosis of adult SE patients. We collected patient's clinical characteristics and laboratory test data. Information of 30-day mortality after SE onset was obtained, and modified Rankin scale (mRS) scores were used to evaluate the clinical outcomes. Multivariable logistic regression models were applied to explore the association between HALP and SE prognosis. Receiver operating characteristic (ROC) curve analysis was performed to determine the optimal cutoff of HALP to predict 30-day mortality in SE patients. Results: We first analyzed the discovery cohort of 116 patients with SE. We observed that 19.0% (22/116) of the patients died within 30 days after SE onset, and 26.3% (20/76) had poor outcomes during the 6-month follow-up. Multivariate logistic regression analysis indicated that lower HALP on admission was an independent predictor of 30-day mortality (odds ratio: 0.980; 95% confidence interval, 0.962-0.999; Conclusion: Lower HALP is independently associated with an increased risk of 30-day mortality and poor functional outcomes in patients with SE. Our findings suggest that HALP may be a promising biomarker for predicting SE prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.